Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $15.60.
Several equities analysts have weighed in on the company. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price objective on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 7th. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. ValuEngine cut Xylem from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, Barclays reiterated a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th.
In other news, Director Anna Kazanchyan sold 10,600 shares of Foamix Pharmaceuticals stock in a transaction on Monday, May 20th. The stock was sold at an average price of $2.61, for a total transaction of $27,666.00. Following the sale, the director now directly owns 55,955 shares in the company, valued at approximately $146,042.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 16,353 shares of company stock worth $41,153 over the last quarter. Company insiders own 2.95% of the company’s stock.
NASDAQ:FOMX traded up $0.06 during trading hours on Friday, hitting $2.37. 2,850 shares of the company traded hands, compared to its average volume of 250,683. The business’s 50-day simple moving average is $2.48. Foamix Pharmaceuticals has a one year low of $2.21 and a one year high of $7.60. The firm has a market cap of $125.73 million, a P/E ratio of -1.38 and a beta of 1.62.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 79.46%. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.95 million. Research analysts predict that Foamix Pharmaceuticals will post -1.61 earnings per share for the current year.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.